Gross Profit (Quarterly)

Gross Profit: Revenues from operations less the associated costs.

KalVista Pharmaceuticals, Inc. (KALV) had Gross Profit of $37.77M for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$40.86M
Net Income	$-23.49M
Cost of Goods Sold	$3.09M
Gross Profit	$37.77M
Operating Expenses	$64.31M
Operating Income	$-23.44M
Non-Operating Income/Expense	$-0.04M
Pre-Tax Income	$-23.49M
Normalized Pre-Tax Income	$-23.49M
Income after Taxes	$-23.49M
Income from Continuous Operations	$-23.49M
Consolidated Net Income/Loss	$-23.49M
Normalized Income after Taxes	$-23.49M
EBIT	$-23.44M
EBITDA	$-23.19M
Weighted-Average Shares Outstanding (Basic)	54.58M
Weighted-Average Shares Outstanding (Diluted)	54.58M
Earnings per Share (EPS) (Basic)	$-0.43
Earnings per Share (EPS) (Diluted)	$-0.43
Balance Sheet Financials
Current Assets	$314.20M
Property, Plant, and Equipment	$2.84M
Long-Term Assets	$14.71M
Total Assets	$328.92M
Current Liabilities	$60.82M
Long-Term Debt	$139.40M
Long-Term Liabilities	$287.75M
Total Liabilities	$348.57M
Common Equity	$-19.65M
Tangible Shareholders Equity	$-19.65M
Shareholders Equity	$-19.65M
Common Shares Outstanding	51.24M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-14.46M
Cash Flow from Investing Activities	$-0.90M
Cash Flow from Financial Activities	$1.47M
Beginning Cash	$230.15M
End Cash	$214.57M
Increase/Decrease in Cash	$-15.57M
Stock-Based Compensation	$5.07M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.17
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	1.16
Debt to Equity Ratio	-7.09
Gross Margin	92.44%
Operating Margin	-57.37%
EBIT Margin	-57.37%
EBITDA Margin	--
Pre-Tax Profit Margin	-57.48%
Profit Margin	-57.48%
Free Cash Flow	$-14.66M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.12
Inventory Turnover	0.77
Receiveable Turnover	2.36
Days Sales in Receivables	38.16
Return on Equity	119.51%
Return on Tangible Equity	119.51%
Return on Assets	-7.14%
Return on Investments	-19.61%
Book Value Per Share	$-0.38
Free Cash Flow per Share	$-0.27
Operating Cash Flow per Share	$-0.26

Data from Zacks Investment Research, Inc.